RSS-Feed abonnieren

DOI: 10.1055/s-0044-1788308
Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry
Funding None declared.

Abstract
Introduction Gastric cancer has become the third leading cause of cancer deaths globally. It accounts for 5.7% of cancer around the world, with a rate of mortality around 8.2%. Evaluation of human epidermal growth factor receptor 2 (HER2)/neu overexpression for targeted therapies is presently the mainstay of treatment in gastric cancer. High Ki-67 index expression in gastric cancer is an indicator of poor prognosis.
Objectives To study the prevalence of HER2/neu expression and Ki-67 index in various types, sites, grade, and stage of gastric adenocarcinoma and to determine the correlation between HER2/neu expression and Ki-67 index.
Materials and Methods This is a prospective study in a tertiary care hospital, Kolkata from January 2019 to June 2020. Gastrectomy and endoscopic biopsy of gastric adenocarcinoma were studied for histopathology and immunohistochemistry (HER2/neu and Ki-67 index). Statistical analysis used: SPSS (version 21.0, IBM, Chicago, Illinois, United States) for windows software.
Results Among 54 cases, most of them were intestinal type, antral, moderately differentiated, stage III cases. HER2 expression and high Ki-67 index were observed in 28.0 and 40.75% cases, respectively. Statistically significant correlation was found in both HER2 expression and high Ki-67 index with location of the tumor and pathological nodal (pN) stage. A positive correlation was found between HER2/neu score and Ki-67 index (p = 0.007) (correlation coefficient = 0.4).
Conclusion A positive correlation was found between HER2/neu positivity and high Ki-67 index, both were associated with higher pathological tumor stage and pN stage. So, advanced cases may be considered for targeted therapy using trastuzumab.
Publikationsverlauf
Artikel online veröffentlicht:
18. Juli 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- 2 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2018
- 3 Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013; 107 (03) 230-236
- 4 Brooks-Wilson AR, Kaurah P, Suriano G. et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004; 41 (07) 508-517
- 5 Ieni A, Barresi V, Rigoli L, Caruso RA, Tuccari G. HER2 status in premalignant, early, and advanced neoplastic lesions of the stomach. Dis Markers 2015; 2015: 234851
- 6 Tzanakis NE, Peros G, Karakitsos P. et al. Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 2009; 109 (05) 606-611
- 7 Hofmann M, Stoss O, Shi D. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52 (07) 797-805
- 8 Dowsett M, Nielsen TO, A'Hern R. et al; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103 (22) 1656-1664
- 9 Amrani HJ, Marchoudi N, Sadaoui I. et al. Ki-67 expression in gastric cancer and correlation with clinico-pathological characteristics. . Int J Sci Res Publ 2018;4(06) ISSN: 2250-3153
- 10 Ahadi M, Moradi A, Musavinejad L, Movafagh A, Moradi A. The Expression of p53, CD44, Ki-67, and HER-2/neu markers in gastric cancer and its association with histopathological indicators: a retrospective study. Asian Pac J Cancer Prev 2020; 21 (06) 1607-1614
- 11 Aditi R, Aarathi R, Pradeep R, Hemalatha L, Akshatha C, Amar K. HER2 expression in gastric adenocarcinoma—a study in a tertiary care centre in south India. Indian J Surg Oncol 2016; 7 (01) 18-24
- 12 Mohapatra D, Chakraborty K, Das D. et al. Significance of HER 2/neu in gastric adenocarcinomas, a clinicopathological correlation. JMSCR 2020; 08 (04) 481-487
- 13 Shah K, Bamanikar S, Pathak P, Chandan Wale SS, Bamanikar A. Immunohistochemical testing of HER2/neu protein overexpression in gastric cancer specimens and its clinicopathological correlation. IP J Diagn Pathol Oncol 2019; 4 (01) 9-15
- 14 Shabbir A, Qureshi MA, Khalid AB, Mirza T, Shaikh A, Hasan SM. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. Saudi J Gastroenterol 2018; 24 (05) 289-293
- 15 Raj N, Verma D, Kumar A, Rai P, Rao RN. HER2 oncogene amplification and immunohistochemical profiling in gastric adenocarcinoma. Discoveries (Craiova) 2018; 6 (04) e83
- 16 Pramanik P, Sarkar R, Maity M. Study of HER2/NEU and Ki-67 expression in gastric and esophagogastric junction adenocarcinoma and their correlation with grade and stage. . Int J Sci Res 2020;9(02)
- 17 Ghosh P, Chakraborty I, Bhowmick S. et al. Overexpression of HER2/neu in gastric carcinoma: association with histological type, tumor grade and H. pylori infection. Ann Pathol Lab Med 2016; 3 (03) A183-A188
- 18 Dawa SK, Zedan EMS. Human epidermal growth factor 2 status in gastric adenocarcinoma. Egypt J Pathol 2018; 38 (01) 126-130
- 19 El-Gendi S, Talaat I, Abdel-Hadi M. HER-2/neu status in gastric carcinomas in a series of Egyptian patients and its relation to Ki-67 expression. Open J Pathol 2015; 5 (04) 101
- 20 Fradique AC, Da Costa LB, Pupo P. et al. The prognostic value of Ki-67 in gastric cancer. J Clin Oncol 2013; 31: e15172-e15172
- 21 Lazăr D, Tăban S, Sporea I. et al. Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol 2010; 51 (04) 655-661
- 22 Ahmed A, Al-Tamimi DM. Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma. Libyan J Med 2018; 13 (01) 1466573